RFCA
PACB icon

R&F Capital Advisors’s Pacific Biosciences PACB Stock Holding History

R&F Capital Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-17,298
Closed -$66K – 792
2016
Q4 		$66K Buy
+17,298
New +$126K 0.02% 465

Other funds holding PACB

Credit Agricole
Credit Agricole Montrouge Cedex, France $49.3B AUM 36.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

R&F Capital Advisors's PACB Position: Q1 2017 in Review

R&F Capital Advisors sold out of Pacific Biosciences (PACB) in Q1 2017, closing a stake of 17,298 shares — an estimated $66K sold.

R&F Capital Advisors first reported a position in PACB in Q4 2016 and held it in 1 quarter. The position peaked at $66K in Q4 2016. 106 funds tracked by Wall St. Rank hold PACB as of Q1 2017.

  • R&F Capital Advisors reported no remaining Pacific Biosciences position as of Q1 2017 after selling out during the quarter.
  • R&F Capital Advisors sold 17,298 Pacific Biosciences shares in Q1 2017, an estimated $66K.
  • R&F Capital Advisors first reported a position in Pacific Biosciences in Q4 2016 and held it in 1 quarter.
  • R&F Capital Advisors's Pacific Biosciences position peaked at $66K in Q4 2016.
  • 106 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.